BitcoinSistemi
2025-07-23 21:26:07

Altcoin Craze Continues Among Companies in the US: They Are Purchasing $100 Million Worth of a Surprise Coin

US-based publicly traded pharmaceutical company MEI Pharma has raised $100 million in private equity capital, adopting a new corporate strategy focused on Litecoin (LTC). The company sold 29,239,767 shares at $3.42 per share, raising a total of approximately $100 million. Litecoin Foundation founder Charlie Lee led this private equity raise and was joined in the deal by digital asset market maker GSR. Lee will also join MEI Pharma's board of directors, while GSR will serve as the company's treasury management advisor. Related News: BREAKING: Tesla Releases Earnings Report - Did It Sell or Buy Bitcoin? MEI Pharma joins the ranks of companies integrating cryptocurrencies into their corporate treasuries. In March, Canada-based Luxxfolio also added Litecoin to its corporate treasury with its first purchase of 4,982 LTC. MEI's Litecoin move has placed it among the companies following in the footsteps of software company Strategy. Strategy has transitioned from software development to a Bitcoin acquisition strategy and currently holds over $72 billion in BTC. According to data from Bitcointreasuries.net, 145 publicly traded companies currently hold a total of $108 billion worth of Bitcoin. *This is not investment advice. Continue Reading: Altcoin Craze Continues Among Companies in the US: They Are Purchasing $100 Million Worth of a Surprise Coin

Get Crypto Newsletter
Read the Disclaimer : All content provided herein our website, hyperlinked sites, associated applications, forums, blogs, social media accounts and other platforms (“Site”) is for your general information only, procured from third party sources. We make no warranties of any kind in relation to our content, including but not limited to accuracy and updatedness. No part of the content that we provide constitutes financial advice, legal advice or any other form of advice meant for your specific reliance for any purpose. Any use or reliance on our content is solely at your own risk and discretion. You should conduct your own research, review, analyse and verify our content before relying on them. Trading is a highly risky activity that can lead to major losses, please therefore consult your financial advisor before making any decision. No content on our Site is meant to be a solicitation or offer.